NeuroPace's RNS System IGE Expansion Hits FDA Roadblock — PMA Supplement Not Approvable
NPCE sits 62% above its 52-week low of $7.563.
Summary
NeuroPace received an FDA communication that its PMA supplement for IGE indication expansion is not approvable in its current form, with additional clinical evidence requested. The company plans to submit a Submission Issue Request and continue working with the FDA, but the setback delays a major growth opportunity.
Key Events · Product Development and Regulatory · NPCE
-
FDA Rejects PMA Supplement in Current Form
The FDA indicated that the PMA supplement for expanding the RNS System label into drug-resistant IGE is not approvable, requesting additional clinical evidence from the NAUTILUS trial and literature.
-
Company to Submit SIR and Continue Dialogue
NeuroPace will submit a Submission Issue Request (SIR) to discuss its planned approach with the FDA and intends to amend the submission with supplemental information, including additional NAUTILUS data.
-
24-Month NAUTILUS Data Shows Durable Benefit
Among evaluable participants with 24-month follow-up, those receiving stimulation for 23 of 24 months achieved a median 100% reduction in GTC seizures, underscoring potential efficacy.
-
IGE Indication Not in Current Guidance
Management's financial guidance does not include any contribution from the expanded IGE indication, limiting immediate financial impact but removing a near-term catalyst.
Analysis · NPCE · Industrial Applications And Services
The FDA has informed NeuroPace that its PMA supplement to expand the RNS System label into drug-resistant idiopathic generalized epilepsy (IGE) is not approvable in its current form, requesting additional clinical evidence. This is a significant setback for a key growth catalyst — the IGE indication represents a large, underserved market with no approved neuromodulation devices. While the company emphasizes continued dialogue and a path forward, the delay introduces uncertainty around the timeline and ultimate approval. The stock may react negatively as the market had priced in some probability of near-term approval. Management notes that guidance did not include IGE contribution, cushioning the financial impact, but the regulatory overhang will persist.
At the time of this filing, NPCE was trading at $12.26 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $522M. The 52-week trading range was $7.56 to $19.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.